MedPage Today July 16, 2024
— Ensuring medication access does not have to come at the cost of innovation
In calling prices for obesity and diabetes medications such as semaglutide (Wegovy, Ozempic) “outrageous” and “unconscionably high,” President Joe Biden and Sen. Bernie Sanders (I.-Vt.) are engaging in a familiar, misguided discourse on prescription drug prices — in this case, they’re targeting a class of weight loss drugs called glucagon-like peptide-1 (GLP-1) receptor agonists.
We have heard this before with regard to vaccines and insulin. Consider Sen. Sanders’ COVID-19 vaccine rhetoric, which has been cited as misleading with regard to the degree of public investment in the vaccines and policies that shielded patients from paying exorbitant prices. Despite this, Sanders has even gone as far as...
Today's Sponsors
Today's Sponsor